Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Rapid detection and quantification of apolipoprotein L1 genetic variants and total levels in plasma by ultra-performance liquid chromatography/tandem mass spectrometry.

Zhou H, Hoek M, Yi P, Rohm RJ, Mahsut A, Brown P, Saunders J, Chmielowski RA, Ren N, Shuster D, Southwick K, Ayanoglu G, Gorman D, Laface D, Santino S, Conway J, Liu Z, Cully D, Cleary M, Roddy TP, Blom D.

Rapid Commun Mass Spectrom. 2013 Dec 15;27(23):2639-47. doi: 10.1002/rcm.6734.

PMID:
24591025
2.

Plasma Levels of Risk-Variant APOL1 Do Not Associate with Renal Disease in a Population-Based Cohort.

Kozlitina J, Zhou H, Brown PN, Rohm RJ, Pan Y, Ayanoglu G, Du X, Rimmer E, Reilly DF, Roddy TP, Cully DF, Vogt TF, Blom D, Hoek M.

J Am Soc Nephrol. 2016 Oct;27(10):3204-3219. Epub 2016 Mar 22.

PMID:
27005919
3.

Characterization of circulating APOL1 protein complexes in African Americans.

Weckerle A, Snipes JA, Cheng D, Gebre AK, Reisz JA, Murea M, Shelness GS, Hawkins GA, Furdui CM, Freedman BI, Parks JS, Ma L.

J Lipid Res. 2016 Jan;57(1):120-30. doi: 10.1194/jlr.M063453. Epub 2015 Nov 18.

4.

Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.

Freedman BI, Langefeld CD, Murea M, Ma L, Otvos JD, Turner J, Antinozzi PA, Divers J, Hicks PJ, Bowden DW, Rocco MV, Parks JS.

Nephrol Dial Transplant. 2011 Nov;26(11):3805-10. doi: 10.1093/ndt/gfr542. Epub 2011 Sep 19.

5.

APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans.

Kasembeli AN, Duarte R, Ramsay M, Mosiane P, Dickens C, Dix-Peek T, Limou S, Sezgin E, Nelson GW, Fogo AB, Goetsch S, Kopp JB, Winkler CA, Naicker S.

J Am Soc Nephrol. 2015 Nov;26(11):2882-90. doi: 10.1681/ASN.2014050469. Epub 2015 Mar 18.

6.

Apolipoprotein L1 and Kidney Disease in African Americans.

Friedman DJ, Pollak MR.

Trends Endocrinol Metab. 2016 Apr;27(4):204-15. doi: 10.1016/j.tem.2016.02.002. Epub 2016 Mar 3. Review.

7.

Plasma apolipoprotein L1 levels do not correlate with CKD.

Bruggeman LA, O'Toole JF, Ross MD, Madhavan SM, Smurzynski M, Wu K, Bosch RJ, Gupta S, Pollak MR, Sedor JR, Kalayjian RC.

J Am Soc Nephrol. 2014 Mar;25(3):634-44. doi: 10.1681/ASN.2013070700. Epub 2013 Nov 14.

8.

Protein domains of APOL1 and its risk variants.

Lan X, Wen H, Lederman R, Malhotra A, Mikulak J, Popik W, Skorecki K, Singhal PC.

Exp Mol Pathol. 2015 Aug;99(1):139-44. doi: 10.1016/j.yexmp.2015.06.003. Epub 2015 Jun 17.

9.

Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population.

Behar DM, Kedem E, Rosset S, Haileselassie Y, Tzur S, Kra-Oz Z, Wasser WG, Shenhar Y, Shahar E, Hassoun G, Maor C, Wolday D, Pollack S, Skorecki K.

Am J Nephrol. 2011;34(5):452-9. doi: 10.1159/000332378. Epub 2011 Oct 3.

PMID:
21968148
10.

APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease.

Tzur S, Rosset S, Skorecki K, Wasser WG.

Nephrol Dial Transplant. 2012 Apr;27(4):1498-505. doi: 10.1093/ndt/gfr796. Epub 2012 Feb 22.

PMID:
22357707
11.

Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.

Freedman BI, Julian BA, Pastan SO, Israni AK, Schladt D, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Hicks PJ, Palmer ND, Adams PL, Palanisamy A, Reeves-Daniel AM, Divers J.

Am J Transplant. 2015 Jun;15(6):1615-22. doi: 10.1111/ajt.13223. Epub 2015 Mar 24.

12.

Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.

Freedman BI, Langefeld CD, Turner J, Núñez M, High KP, Spainhour M, Hicks PJ, Bowden DW, Reeves-Daniel AM, Murea M, Rocco MV, Divers J.

Kidney Int. 2012 Oct;82(7):805-11. doi: 10.1038/ki.2012.217. Epub 2012 Jun 13.

13.

APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.

Olabisi OA, Zhang JY, VerPlank L, Zahler N, DiBartolo S 3rd, Heneghan JF, Schlöndorff JS, Suh JH, Yan P, Alper SL, Friedman DJ, Pollak MR.

Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):830-7. doi: 10.1073/pnas.1522913113. Epub 2015 Dec 23.

14.

APOL1 genetic variants, chronic kidney diseases and hypertension in mixed ancestry South Africans.

Matsha TE, Kengne AP, Masconi KL, Yako YY, Erasmus RT.

BMC Genet. 2015 Jun 26;16:69. doi: 10.1186/s12863-015-0228-6.

15.

Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1.

Sharma AK, Friedman DJ, Pollak MR, Alper SL.

FEBS J. 2016 May;283(10):1846-62. doi: 10.1111/febs.13706. Epub 2016 Apr 1.

16.

Sequencing rare and common APOL1 coding variants to determine kidney disease risk.

Limou S, Nelson GW, Lecordier L, An P, O'hUigin CS, David VA, Binns-Roemer EA, Guiblet WM, Oleksyk TK, Pays E, Kopp JB, Winkler CA.

Kidney Int. 2015 Oct;88(4):754-63. doi: 10.1038/ki.2015.151. Epub 2015 May 20.

17.

Population genetics of chronic kidney disease: the evolving story of APOL1.

Wasser WG, Tzur S, Wolday D, Adu D, Baumstein D, Rosset S, Skorecki K.

J Nephrol. 2012 Sep-Oct;25(5):603-18. doi: 10.5301/jn.5000179. Review.

PMID:
22878977
18.

Copy Number Variation at the APOL1 Locus.

Ruchi R, Genovese G, Lee J, Charoonratana VT, Bernhardy AJ, Alper SL, Kopp JB, Thadhani R, Friedman DJ, Pollak MR.

PLoS One. 2015 May 1;10(5):e0125410. doi: 10.1371/journal.pone.0125410. eCollection 2015.

19.

In vivo Modeling Implicates APOL1 in Nephropathy: Evidence for Dominant Negative Effects and Epistasis under Anemic Stress.

Anderson BR, Howell DN, Soldano K, Garrett ME, Katsanis N, Telen MJ, Davis EE, Ashley-Koch AE.

PLoS Genet. 2015 Jul 6;11(7):e1005349. doi: 10.1371/journal.pgen.1005349. eCollection 2015 Jul. Erratum in: PLoS Genet. 2015 Sep;11(9):e1005459.

20.

High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-eastern Nigeria.

Ulasi II, Tzur S, Wasser WG, Shemer R, Kruzel E, Feigin E, Ijoma CK, Onodugo OD, Okoye JU, Arodiwe EB, Ifebunandu NA, Chukwuka CJ, Onyedum CC, Ijoma UN, Nna E, Onuigbo M, Rosset S, Skorecki K.

Nephron Clin Pract. 2013;123(1-2):123-8. doi: 10.1159/000353223. Epub 2013 Jul 13.

PMID:
23860441

Supplemental Content

Support Center